Publications by authors named "D Mishkin"

Introduction: A new bowel preparation for colonoscopy has been developed containing poorly absorbed sulfate salts and polyethylene glycol 3350, which retain water within the intestinal lumen resulting in copious diarrhea, thereby cleansing the bowel. The product was formulated to be safe and effective with a sports drink-like flavor. This study evaluated the new flavored polyethylene glycol and sulfate solution (FPSS) compared with a Food and Drug Administration-approved bowel preparation containing sulfate salts only [oral sulfate solution (OSS)].

View Article and Find Full Text PDF

Background: To demonstrate treatment efficacy in Crohn's disease (CD), regulatory authorities require that trials include an endoscopic remission/response end point; however, standardized endoscopic assessment of disease activity, such as the Simple Endoscopic Score for Crohn's Disease (SES-CD), is not typically recorded by clinicians in practice or outside of clinical trials. The novel Simplified Endoscopic Mucosal Assessment for Crohn's Disease (SEMA-CD) was developed to be easy to use in routine clinical practice and as a trial end point. We conducted a study to assess and validate the reliability and feasibility of SEMA-CD as a measure of endoscopic disease activity.

View Article and Find Full Text PDF
Article Synopsis
  • Etrolizumab is an anti-β7 integrin monoclonal antibody that showed promise in improving remission rates for patients with moderately to severely active ulcerative colitis in previous studies, leading to the HIBISCUS trials to further assess its effectiveness compared to adalimumab and placebo.
  • The HIBISCUS studies were multicenter, double-blind, randomized trials involving adult patients with specific inclusion criteria, randomly assigning participants to receive etrolizumab, adalimumab, or placebo while ensuring that both the patients and study staff remained unaware of the treatment assignments.
  • The main goal of these studies was to measure remission rates at week 10, using a specific formula to define remission, while also performing
View Article and Find Full Text PDF

Purpose: Celiac disease (CD) is a permanent immune reaction to gluten that is likely related to genetic factors. Some studies have linked CD to adverse maternal and/or neonatal outcomes but the data has been contradictory. The purpose of this study was to evaluate the effect of CD on pregnancy outcomes.

View Article and Find Full Text PDF